PRXL2A: A Potential Drug Target for Pain, Inflammation and Neurotransmission

Target Name: PRXL2A

NCBI ID: G84293

PRXL2A

PRXL2A: A Potential Drug Target for Pain, Inflammation and Neurotransmission

PRXL2A, also known as Adrx, is a protein that is expressed in the brain and is known for its role in the regulation of pain and inflammation. The protein is a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

PRXL2A is a transmembrane protein that is expressed in the brain and is involved in the regulation of pain perception, inflammation, and neurotransmitter signaling. The protein is composed of four transmembrane segments and has an extracellular domain that is involved in interactions with other proteins.

The most well-studied function of PRXL2A is its role in pain regulation. PRXL2A is known to play a role in the regulation of pain perception and has been shown to interact with various pain receptors, including nociceptors and endogenous opioids. This suggests that PRXL2A may be involved in the regulation of pain perception and could potentially be a drug target for pain relief.

In addition to its role in pain regulation, PRXL2A is also known to be involved in the regulation of inflammation. Studies have shown that PRXL2A is involved in the regulation of inflammation in the brain and that its expression is decreased in diseases such as Alzheimer's disease and multiple sclerosis. This suggests that PRXL2A may be a potential drug target for these disorders.

PRXL2A is also known to be involved in neurotransmitter signaling in the brain. Studies have shown that PRXL2A is involved in the regulation of dopamine release and that its expression is affected by neurotransmitters such as dopamine. This suggests that PRXL2A may be involved in the regulation of neurotransmitter signaling in the brain and could potentially be a drug target for neurotransmitter-related disorders.

The potential drug targets for PRXL2A are vast and include various neurological and psychiatric disorders. PRXL2A is a potential drug target for pain relief, as its involvement in pain regulation makes it a promising target for pain relief medications. PRXL2A is also a potential drug target for Alzheimer's disease, as its expression is decreased in this disease and its involvement in the regulation of neurotransmitter signaling suggests that it may be involved in the regulation of neurodegeneration.

PRXL2A is also a potential drug target for Parkinson's disease, as its expression is decreased in this disease and its involvement in the regulation of neurotransmitter signaling suggests that it may be involved in the regulation of neurodegeneration. PRXL2A may also be a potential drug target for multiple sclerosis, as its expression is decreased in this disease and its involvement in the regulation of neurotransmitter signaling suggests that it may be involved in the regulation of neurodegeneration.

In conclusion, PRXL2A is a protein that is involved in the regulation of pain, inflammation, and neurotransmitter signaling. Its potential drug targets include pain relief, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Further research is needed to fully understand the role of PRXL2A in these disorders and to develop effective treatments.

Protein Name: Peroxiredoxin Like 2A

Functions: Involved in redox regulation of the cell (PubMed:26438880, PubMed:19951071). Acts as an antioxidant (PubMed:19951071, PubMed:26438880). Inhibits TNFSF11-induced NFKB1 and JUN activation and osteoclast differentiation (PubMed:19951071). May affect bone resorption and help to maintain bone mass (PubMed:19951071). Acts as a negative regulator of macrophage-mediated inflammation by inhibiting macrophage production of inflammatory cytokines, probably through suppression of the MAPK signaling pathway (PubMed:26438880)

The "PRXL2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRXL2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets